GlassScriptPhysician profile
David R Brown
NPI 1114044906
$496,761.04
in general payments reported to CMS, 2019-2025
12 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $46K · 2021: $109K · 2022: $96K · 2023: $22K · 2024: $57K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Honoraria: $32K · Consulting Fee: $13K · Travel and Lodging: $12K · Food and Beverage: $2,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,205.00 |
| Honoraria | $32,020.75 |
| Consulting Fee | $12,997.50 |
| Travel and Lodging | $12,069.09 |
| Food and Beverage | $2,352.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $280,251.32 | 2019-2025 | Korlym |
| Novo Nordisk INC | $204,065.83 | 2019-2024 | Ozempic |
| Merck Sharp & Dohme LLC | $8,494.45 | 2019-2020 | |
| Biomarin Pharmaceutical INC. | $3,240.00 | 2022 | |
| Beta Bionics, INC. | $144.19 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Aerin Medical INC. | $143.84 | 2025 | |
| Dexcom, INC. | $125.00 | 2025 | Dexcom G7 Gss (161) |
| Mentor Worldwide LLC | $120.55 | 2019 | |
| Lilly USA, LLC | $69.11 | 2022 | |
| Radius Health, INC. | $50.56 | 2025 | Tymlos |
| Amgen INC. | $37.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.